Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

समान संसाधन

• Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus
  द्वारा: Furie, Richard, और अन्य
  प्रकाशित: (2017)
• Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus
  द्वारा: Merrill, Joan T, और अन्य
  प्रकाशित: (2018)
• Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients
  द्वारा: Zheng, Bo, और अन्य
  प्रकाशित: (2016)
• Sifalimumab, a Human Anti–Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study: A Phase I Randomized, Controlled, Dose-Escalation Study
  द्वारा: Petri, Michelle, और अन्य
  प्रकाशित: (2013)
• A double-blind, randomized, placebo-controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus
  द्वारा: Werth, V.P., और अन्य
  प्रकाशित: (2019)